Human growth hormone conjugated with biocompatible polymer
The present invention relates to conjugates of biocompatible polymers and hGH, particularly PEG-hGH, where the activated biocompatible polymer is conjugated to a carboxyl group of hGH at a molar ratio of 1:1, methods of preparation, and related pharmaceutical compositions. The PEG-hGH conjugates have up to 20% of the activity of the native hGH while the in vivo half life is increased 10 fold. The PEG-hGH conjugates may be used therapeutically to treat growth retardation or growth failure, especially short stature in children, and conditions related to aging.
1 . A conjugate of biocompatible polymer-human Growth Hormone (hGH), wherein the biocompatible polymer is conjugated to a carboxyl group of hGH at a molar ratio of 1:1.
2 . The conjugate according to claim 1 , wherein the biocompatible polymer is selected from the group consisting of polyethylene glycol, polypropylene glycol, polyoxyethylene, polytrimethylene glycol, polylactic acid and derivatives thereof, polyacrylic acid and derivatives thereof, poly(amino acid), polyurethane, polyphosphazene, poly(L-lysine), polyalkylene oxide, polysaccharide, dextran, polyvinyl pyrrolidone, polyvinyl alcohol, polyacrylamide, and copolymers thereof.
3 . The conjugate according to claim 1 , wherein the biocompatible polymer is selected from the group consisting of PEG-20000 and PEG-30000.
4 . A pharmaceutical composition comprising a pharmaceutically acceptable amount of the conjugate according to claim 1 and a pharmaceutically acceptable carrier.
5 . The conjugate of claim 1 , wherein the carboxyl group is the C-terminus of hGH.
6 . The conjugate of claim 1 , wherein the activity of the conjugate is 10-20% of the activity of an unconjugated hGH protein.
7 . A method of preparing a conjugate of biocompatible polymer-hGH comprising:
(a) activating a biocompatible polymer with the stepwise addition of a coupling reagent; and
(b) conjugating the activated biocompatible polymer to a carboxyl group of the hGH at a molar ratio of 1:1,
wherein the molar ratio of the hGH to the activated biocompatible polymer is 1:1 to 1:20, the ratio of the hGH to the coupling reagent is 1:1 to 1:50, and pH is in the range of 2 to 5.
8 . The method according to claim 7 , wherein the biocompatible polymer is activated with a reactive functional group which is able to react with a carboxylic acid and/or a reactive carbonyl group.
9 . The method according to claim 7 , wherein the biocompatible polymer is selected from the group consisting of polyethylene glycol, polypropylene glycol, polyoxyethylene, polytrimethylene glycol, polylactic acid and derivatives thereof, polyacrylic acid and derivatives thereof, poly(amino acid), polyurethane, polyphosphazene, poly(L-lysine), polyalkylene oxide, polysaccharide, dextran, polyvinyl pyrrolidone, polyvinyl alcohol, polyacrylamide, and copolymers thereof.
10 . The method according to claim 7 , wherein the biocompatible polymer is selected from the group consisting of PEG-20000 and PEG-30000.
11 . The method of claim 7 , wherein the carboxyl group is the C-terminus of hGH.
12 . The method of claim 7 , further comprising:
(c) purifying the conjugate by size exclusion chromatography;
(d) precipitating the conjugate of (c) using ammonium sulfate;
(e) purifying the conjugate of (d) by ion exchanges chromatography; and
(f) purifying the conjugate of (e) by hydrophobic interaction chromatography.
13 . The conjugate of biocompatible polymer-hGH prepared according to claim 7 , wherein the biocompatible polymer is conjugated to a carboxyl group of the hGH at a molar ratio of 1:1.
14 . The conjugate of claim 5 , wherein the biocompatible polymer is PEG.
15 . The conjugate of claim 5 which has 10-20% of the activity of unconjugated hGH protein.
16 . A method of treating growth failure or growth retardation by administering an effective amount of a composition comprising PEG-hGH to a patient in need thereof, wherein the PEG is conjugated to a carboxyl group of hGH at a molar ratio of 1:1.
17 . The method according to claim 16 , wherein the carboxyl group is the C-terminus of hGH.
18 . The method of claim 16 , wherein the PEG-hGH has 10-20% of the activity of unconjugated hGH protein.
19 . The method according to claim 16 , wherein the growth failure or growth retardation is due to homone deficiency, chronic renal disease, Turner's syndrome, cachexia or AIDS wasting.
20 . The method according to claim 16 , wherein the PEG-hGH is administered in combination with a pharmaceutically acceptable carrier.
21 . The method according to claim 16 , wherein the administration is done by injection.
22 . The method according to claim 16 , wherein the administration is oral.
23 . The method according to claim 16 , wherein the composition is administered no more than twice per week to the patient in need thereof.
24 . A method of treating short stature in children by administering an effective amount of a composition comprising PEG-hGH to a patient in need thereof at a frequency of no more than twice/week, wherein the PEG is conjugated to a C-terminus carboxyl group of hGH at a molar raio of 1:1 and the PEG-hGH has 10-20% of the activity of unconjugated hGH.
25 . A method of treating adverse effects associated with aging selected from the group consisting of decrease in lean muscle, increase in blood pressure, increase in cholesterol, increase in body fat, loss of skin tone, and decrease in bone density by administering an effective amount of a composition comprising PEG-hGH to a patient in need thereof, wherein the PEG is conjugated to a carboxyl group of hGH at a molar raio of 1:1.
26 . A kit comprising:
the conjugate of claim 1 in lyophillized form;
a pharmaceutically acceptable carrier for reconstitution of the conjugate; and
a delivery device for delivery of the reconstituted conjugate to a patient in need thereof.
27 . The kit of claim 26 , further comprising:
a skin antiseptic; and
an instruction sheet.
28 . A kit comprising the conjugate of claim 1 preloaded in a syringe.